In the project, SpectraCure will collaborate with Philips Innovation Services in the Netherlands, and CSEM SA in Switzerland. The aim of the project is to adapt SpectraCure's system for PDT treatment, the P18 system, for series production, by shortening the production time. Today, the P18 units are manufactured with manual assembly in SpectraCure's production premises in Lund.
Philips MEMS & Micro Devices has extensive experience in the manufacture of medical devices and will be main responsible for the project. CSEM SA is specialized in the development of electronics and photonics and will contribute with expert knowledge in technology development.
The project's total budget is approximately € 166,000, of which € 125,000 are grants and the rest is contributed by SpectraCure. The project is planned to be completed in 2022.
“This is gratifying and an important step towards increasing the degree of automation in the future and outsourcing parts of the assembly to subcontractors. In the long run, the goal is to enable series production and to significantly reduce manufacturing costs per system,” says SpectraCure's CEO Johan Folkunger.
For information about MedPhab, see https://medphab.eu/
For further information:
SpectraCure AB (publ) Johan Folkunger, CEO
E-mail: jf@spectracure.com
Website: www.spectracure.com
SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system consisting of a hardware device, a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, safe for every patient. The goal is that in addition to being tumor free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system.
The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, ca@gwkapital.se, tel +468-503 00 050, and trades under the short name SPEC.
